Metastatic Colorectal Cancer Pipeline and Clinical Trials Assessment (2023) | Companies- G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shangh

(Albany, 08 June 2023), DelveInsight's "Metastatic Colorectal Cancer Pipeline Insight 2023" report offers extensive knowledge on more than 140+ companies and 140+ pipeline drugs within the landscape of Metastatic Colorectal Cancer research. The Metastatic Colorectal Cancer Pipeline report provides detailed profiles of the Metastatic Colorectal Cancer pipeline drugs, encompassing both Metastatic Colorectal Cancer clinical trials and nonclinical stage products. Additionally, it assesses the therapeutics based on product type, stage, route of administration, and molecule type. Furthermore, the report sheds light on inactive pipeline products in this field.

The Metastatic Colorectal Cancer pipeline analysis report for Metastatic Colorectal Cancer emerging drugs offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Metastatic Colorectal Cancer pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, Metastatic Colorectal Cancer clinical trial studies conducted for Metastatic Colorectal Cancer, any obtained Metastatic Colorectal Cancer NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.

To explore more information on the latest breakthroughs in the Metastatic Colorectal Cancer Pipeline treatment landscape of the report, click here @ Metastatic Colorectal Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
• DelveInsight's Metastatic Colorectal Cancer Pipeline analysis depicts a robust space with 140+ active players working to develop 140+ pipeline treatment therapies.
• The leading Metastatic Colorectal Cancer Companies are working in the market include G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, AXIMM, AstraZeneca, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and others
• Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, etrumadenant, zimberelimab, mFOLFOX-6 regimen, Pembrolizumab, Binimetinib, Oxaliplatin, FOLFIRI, FOLFOX, Bevacizumab, Oxaliplatin, Leucovorin, and others.
• In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.
• Corsela (Trilaciclib) is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases (CDK) 4 and 6 developed by G1 Therapeutics for its myeloprotection and potential antitumor efficacy and safety benefits in combination with cancer chemotherapy. CDKs govern cell cycle progression, and trilaciclib induces a transient, reversible G1 cell cycle arrest of proliferating hematopoietic stem and progenitor cells in bone marrow, thus protecting them from damage during chemotherapy. It is a novel therapeutic approach, which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two benefits. First, it proactively helps protect HSPCs in bone marrow leading to preservation of neutrophils, erythrocytes, and platelets (called myeloprotection) which reduces the occurrences and severity of neutropenia and other myelosuppressive consequences of chemotherapy.

Metastatic Colorectal Cancer Overview
Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the recttum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common.

For further information, refer to the detailed Metastatic Colorectal Cancer Unmet Needs, Metastatic Colorectal Cancer Market Drivers, and Metastatic Colorectal Cancer Market Barriers, click here for Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Colorectal Cancer Emerging Drugs Profile
• Trilaciclib: G1 Therapeutics
• Famitinib: Jiangsu Hengrui Medicine
• CMAB009: Mabpharm Limitied
• Trastuzumab Deruxtecan: Daiichi Sankyo
• SCO-101: Scandion Oncology
• BEY 1107: BeyondBio
• Etrumadenant: Arcus Biosciences

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
There are approx. 140+ Metastatic Colorectal Cancer companies which are developing the Metastatic Colorectal Cancer therapies. The Metastatic Colorectal Cancer companies which have their Metastatic Colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, G1 Therapeutics.

Request a sample and discover the recent advances in Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Colorectal Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Colorectal Cancer Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Metastatic Colorectal Cancer Therapeutics Market include-
G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, AXIMM, AstraZeneca, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and others

Dive deep into rich insights for drugs for Metastatic Colorectal Cancer Pipeline, click here @ Metastatic Colorectal Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic Colorectal Cancer Pipeline Report
• Coverage- Global
• Metastatic Colorectal Cancer Companies- G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, AXIMM, AstraZeneca, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and others
• Metastatic Colorectal Cancer Pipeline Therapies- CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, etrumadenant, zimberelimab, mFOLFOX-6 regimen, Pembrolizumab, Binimetinib, Oxaliplatin, FOLFIRI, FOLFOX, Bevacizumab, Oxaliplatin, Leucovorin, and others.
• Metastatic Colorectal Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Metastatic Colorectal Cancer Mergers and acquisitions, Metastatic Colorectal Cancer Licensing Activities @ Metastatic Colorectal Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Metastatic Colorectal Cancer Executive Summary
3. Metastatic Colorectal cancer: Overview
4. Metastatic Colorectal Cancer Pipeline Therapeutics
5. Metastatic Colorectal Cancer Therapeutic Assessment
6. Metastatic Colorectal cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Trilaciclib: G1 Therapeutics
9. Metastatic Colorectal Cancer Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. SHR 1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Trastuzumab Deruxtecan: Daiichi Sankyo
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I/II)
17. NKTR-255: Nektar Therapeutics
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Talimogene Laherparepvec: Amgen
21. Drug profiles in the detailed report…..
22. Preclinical and Discovery Stage Products
23. PCS11T: Processa Pharmaceuticals
24. Drug profiles in the detailed report…..
25. Inactive Products
26. Metastatic Colorectal cancer Key Companies
27. Metastatic Colorectal cancer Key Products
28. Metastatic Colorectal cancer- Unmet Needs
29. Metastatic Colorectal cancer- Market Drivers and Barriers
30. Metastatic Colorectal cancer- Future Perspectives and Conclusion
31. Metastatic Colorectal cancer Analyst Views
32. Metastatic Colorectal cancer Key Companies
33. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.